| Aug 7 |
Revolution Medicines Reports Second Quarter 2024 Financial Results and Update on Corporate Progress
|
| Aug 1 |
Collegium Pharmaceutical (COLL) Earnings Expected to Grow: Should You Buy?
|
| Jul 31 |
Revolution Medicines to Report Financial Results for Second Quarter 2024 After Market Close on August 7, 2024
|
| Jul 16 |
Top 3 Health Care Stocks That Should Keep You Up At Night This Quarter
|
| Jul 15 |
Revolution Medicines firms up Phase 3 trial plans with latest cancer drug data
|
| Jul 11 |
Revolution Medicines Announces Publication Demonstrating Robust Anti-Tumor Activity of RAS(ON) Inhibitors in Preclinical Models of Refractory KRAS-Mutated Non-Small Cell Lung Cancer
|
| Jul 10 |
Revolution Medicines (RVMD) Moves 11.0% Higher: Will This Strength Last?
|
| Jul 8 |
Revolution Medicines to Provide Update on RMC-6236 Pancreatic Ductal Adenocarcinoma Clinical Program on July 15, 2024
|
| Jun 20 |
Insider Sale: COO Margaret Horn Sells Shares of Revolution Medicines Inc (RVMD)
|
| Jun 14 |
Shareholders Will Most Likely Find Revolution Medicines, Inc.'s (NASDAQ:RVMD) CEO Compensation Acceptable
|
